INTRODUCTION
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) arise from cells of the embryological gut. Most commonly, the primary lesion is located in the gastric mucosa, the small and large intestine, the rectum and pancreas. 1 These tumours have a common feature represented by the expression of both neural and endocrine markers; thus, they are often referred to as GEP-NET. 2 GEP-NETs have historically been considered as rare tumours, accounting for~0.5% of all human cancers; the incidence is estimated to be 5.25/100 000/year, with a prevalence of 35/100 000/year. 1, 2 The highest incidence of these tumours is from the fifth decade onward, although they can appear at all ages with the exception of the carcinoid of the appendix, which occurs with the highest incidence at ∼ 40 years of age. A slight higher overall incidence of GEP-NETs is observed in males (5.35) compared with females (4.76) and patients affected by multiple endocrine neoplasia type 1 (MEN1) or von Hippel-Lindau's disease (VHL), may have a clinical onset 15-20 years earlier than patients with corresponding sporadic type of neuroendocrine tumours. 3 The relatively low incidence of these tumours is a main reason for the paucity of knowledge regarding their cellular and molecular biology compared with more common cancers. Details of the genetic landscapes of GEP-NETs have recently been published, and in parallel to this genetic profiling, there has also been an increasing interest in the role of epigenetic changes in GEP-NETs. 4 Epigenetics describes a hereditable change in gene expression without a change in the DNA sequence ( Figure 1 ). 5 The key distinguishing feature of epigenetic changes from gene mutations is that the former are potentially reversible with pharmacologic treatments, providing opportunity for therapeutic intervention. During the past 10 years it has become evident that epigenetic abnormalities are as relevant as gene mutations in the pathogenesis of cancer. 5 The most studied epigenetic changes are promoter methylations and, particularly, alterations in DNA methylation in CpG islands, which are mainly located in the upstream promoter regions and are responsible for recruiting inhibitory protein complexes leading to transcriptional repression of the downstream genes. 6 In some tumours, CpG island methylator phenotype (CIMP) is associated with simultaneous abnormal methylation of multiple CpG islands, including several associated with wellknown tumour suppressor genes, such as Rb, VHL, p16, hMLH1 and BRCA1. 7 The maintenance and de novo methylation of DNA are controlled by the enzyme family DNA methyltransferases (DNMTs) that allow hypermethylation following DNA replication. Three families of DNMT genes have been identified: DNMT1 that maintains methylation, DNMT3 consisting of two related gene products (DNMT3a and DNMT3b), responsible for de novo methylation and DNMT2, the function of which remains unknown. 8, 9 Other epigenetic mechanisms also include histone modifications and chromatin remodelling. Histone deacetylases (HDACs) catalyse the removal of acetyl groups from specific lysine side chains in histones, resulting in a closed chromatin structure and subsequent suppression of gene activity. In contrast, histone acetyltransferases mediate the reversible acetylation of histones and non-histone proteins resulting in a local 'open chromatin' allowing transcriptional activation of genes through the binding of multiple transcription factors.
Among post-transcriptional mechanisms microRNAs (miRNAs), small noncoding RNAs of~19-22 nucleotides, are responsible for regulating protein expression by targeting mRNAs for cleavage or translational repression. They represent one of the most abundant classes of gene-regulatory molecules influencing the output of many protein-coding genes.
In the present review we provide an overview of the current knowledge of epigenetic changes relating to GEP-NETs, focusing on the influence and impact these changes have on pathogenesis and prognosis, and the potential role of demethylating agents in patient management.
PANCREATIC NEUROENDOCRINE TUMOURS
Pancreatic neuroendocrine tumours (pNETs) represent 1-2% of all pancreatic neoplasms. They are a heterogeneous group of tumours with an extremely variable clinical behaviour, depending on histologic features and disease staging. pNETs include functioning tumours (40-55%), gastrinomas, insulinomas, gluconomas and VIPomas, as well as non-functioning tumours. Surgical treatment, which is possible when no metastatic disease is present, represents the best chance for a cure. Overall 5-year survival for pNETs varies from 97% for benign insulinomas to 30% for those that are non-functioning and clinically silent.
1 pNETS are the most well characterised of NETs in terms of epigenetic changes, and these epigenetic characteristics in part account for the relative indolent course of insulinomas compared with other pNETS.
Promoter hypermethylation RASSF1. Ras association domain family 1 (RASSF1) has been largely investigated with regards to promoter methylation in GEPNETs. This tumour suppressor gene family consists of eight different isoforms produced by alternative splicing and transcription from different promoters containing CpG islands ( Figure 2 ).
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RASSF1 regulatory region includes two CpG islands: CpG island A in the regulatory region common to RASSF1A, D, E, F, G and CpG island C in the regulatory region of RASSF1C.
11 Isoform A regulates cellular proliferation, apoptosis and stabilization of microtubules, and is frequently methylated in pancreatic, pulmonary and welldifferentiated gastrointestinal NETs. Isoform RASSF1C is overexpressed in pNETs where it is thought to have a role in the regulation of the Wnt pathway, in terms of inhibiting beta-catenin degradation, suggesting that RASSF1C may have a pathogenic role in the development of pNETs. Little is known about the influence of CpG islands on RASSF1B and its function. 11, 12 Aberrant hypermethylation of RASSF1A was detected in 75% of 48 well-differentiated, non-functioning pNETs included in the largest study of methylation in NETs by House et al., 13 with no evidence of methylation in the adjacent normal tissue. The authors found that tumours larger than 5 cm and those with either lymph node or hepatic metastases exhibited a higher frequency of methylation compared with pNETs without malignant histologic features. Furthermore, Malpeli et al. 11 illustrated that in 20 pNETs the expression level of RASSF1A was inversely correlated with gene methylation with the average expression of RASSF1A being 6.8 times lower than in normal tissues (P = 0.003).
CDKN2A. CDKN2A encodes for the tumour suppressor protein, p16, that is responsible for cell entry into the S phase. CDKN2A has been shown to be silent in many tumour types through epigenetic mechanisms.
14,15 CDKN2A methylation has been observed in the pNET cell line QGP1 and, clinically, methylation at the p16 locus has been found to be predictive of both tumour recurrence within 24 months post surgery and with reduced patient survival at 5 years. 13, 16 Muscarella et al. 17 investigated p16 methylation in 12 patients with NETs (eight gastrinomas and four non-functioning pNETs). In this cohort, p16 was methylated in 58% of specimens, with 92% of the samples having inactivating alterations, suggesting that transcriptional silencing of p16 is a frequent event in these tumours. These results were supported by Serrano et al.
14 who reported p16 methylation in 54% of 44 patients with gastrinoma.
Other methylation sites. Other loci have been investigated for their potential involvement in pNET development. Wild et al.
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studied 21 pNETs (nine non-functioning neuroendocrine pancreatic carcinomas, five insulinomas, five gastrinomas, nine VIPoma and one renin-producing pNET) and identified methylation of the tumour suppressor gene tissue inhibitor of metalloproteinase-3 in 8 out of 18 samples (44%), with a correspondent loss or strong reduction in protein expression. The possible role of tissue inhibitor of metalloproteinase-3 in pNET tumorigenesis, particularly for metastatic spread, is supported by the identification of alterations in tissue inhibitor of metalloproteinase-3 in 79% of metastatic pNETs, compared with only 14% of nonmetastatic pNETs.
The status of O6-alkylguanine DNA alkyltransferase (MGMT) in NETs has been also investigated. The expression of this DNA repair enzyme has been shown to correlate with treatment response to temozolomide in several tumour types as the cytotoxic effect of temozolomide can be attributed to its ability to induce DNA methylation at the O6 position of guanine, leading to a DNA mismatch and tumour cell death (Figure 3) . 19 The sensitivity of tumour cells to alkylating agents such as temozolomide has been associated with decreased levels of MGMT, which can prevent chemotherapy-induced cell death through restoration of normal DNA structure. 20 In their study, House et al. 13 and that in patients with a diagnosis of pNETs, MGMT deficiency was associated with improved clinical response to temozolamide. As described earlier, CIMP defines a specific tumour phenotype characterized by frequent promoter methylation of tumour suppressor genes. Arnold et al., 22 in a cohort of 118 GEP-NETs including 28 gastrinomas, 3 glucagonomas, 26 insulinomas (21 benign and 5 malignant), 2 VIPomas, 19 carcinoid and 40 non-functioning NETs, found CIMP in 73% of the samples. The presence of CIMP was associated with worse overall survival compared with CIMP negativity (4 versus 7 years). Subgroup analysis based on stratification according to proliferation index Ki-67 indicated that CIMP-positive tumours with a Ki-67 o 2% had better overall survival compared with those tumours that were CIMP-positive but with a Ki-6742% (7.1 versus 1.6 years). Moreover, tumours that were CIMP-positive with Ki-67o 2% were not associated with the presence of metastases, whereas those that were CIMP-positive with Ki-6742% exhibited a more malignant behaviour, suggesting the potential role of CIMP/Ki67 status as prognostic biomarker. A limitation of this study was the use of descriptive survival analyses, as the authors felt the number of patients evaluated were too small to conduct formal survival statistics. Although provocative, these findings need to be evaluated in a large cohort of patients to establish the prognostic significance of CIMP/Ki67.
Preclinical evidence supports the hypothesis that overexpression of imprinted insulin-like growth factor 2 (IGF2) can be due to hypermethylation of CpG islands in the differentially methylated region 2. Loss of imprinting and overexpression of IGF2 is an epigenetic event that has been described in the development of numerous cancers and has recently been reported in pNETs. 23 Dejeux et al. 24 examined eleven insulinomas, twelve gastrinomas and twenty-nine non-functioning tumours and reported that insulinomas were hypermethylated in three regions associated with IGF2 and that hypermethylation of differentially methylated region 2 was specific for insulinomas, not occurring in gastrinomas or non-functioning pNETs. Notably, reduced levels of methylation of IGF2 were associated with malignancy according to WHO classification, suggesting the potential role of methylation of IGF2 as a further biomarker for classification and staging of pNETs. 25 Another gene that is frequently methylated in insulinomas compared to other pNET subtypes is MutL Homolog 1 (MLH1). Mei et al. 26 observed MLH1 methylation in 31% (15/48) insulinomas with a subsequent reduction in protein expression, associated with the primary malignancy (P = 0.03).
Chromatin remodelling. Chromatin remodelling is a new field of investigation in NETs. In an attempt to define the genetic landscape of pNETs, Jiao et al. 27 found mutations of genes involved in mammalian target of rapamycin (mTOR) pathways. In this study, 43% of 68 pNETs had either ATRX or DAXX gene mutations, 18% and 25%, respectively, both mutations of which were mutually exclusive and associated with better prognosis. This finding suggests that ATRX and DAXX work together in a common pathway relevant for the pathogenesis of pNETs, being of particular interest considering the possible impact on patients' stratification for therapy with mTOR inhibitors.
Chen et al. 28 supported these findings showing loss of ATRX or DAXX immunoreactivity in 41% of 70 pNETs included in their study. Moreover, loss of DAXX correlated with Ki-67, and DAXX immunoreactivity positively correlated with histologic grade, in keeping with the hypothesis that loss of ATRX or DAXX proteins in NETs is different from the tissue of origin of the tumour and suggesting a possible site-specific role in pNET development. Mutations in ATRX/DAXX are mutually exclusive; however, the presence of combined mutations of either ATRX or DAXX with multiple endocrine neoplasia type 1 mutations exhibited superior survival, with 100% of patients with these mutations having an overall survival of at least 10 years, whereas in those without the presence of these mutations, 60% died within 5 years of diagnosis. 25 Figure 2. Representation of RASSF1A pathways. Following mitogenic or apoptotic stimuli, RASSF1A binds to microtubule-binding proteins regulating mitosis, cell cycle and apoptosis. RASSF1A localizes to microtubules after the interaction between microtubule-associated proteins, thus, regulating mitosis; cell cycle arrest is the consequence of repression of cyclins A and D1 by RASSF1A. Finally, apoptosis can be modulated by of RASSF1A with CNK1, MST1, Salvador and MOAP1.
The link between nuclear protein expression of ATRX or DAXX and ALT status has been investigated in patients with pNETs associated with MEN1. 29 In this study, twenty-eight pNETs and forty-seven microadenomas were included. ATRX and DAXX expression was present in all microadenomas, none of which exhibited the ALT phenotype. Conversely, 6% of pNETs had loss of ATRX and/or DAXX and demonstrated ALT phenotype. Furthermore, of the three tumours that presented with lymph node metastases, two exhibited the same changes as the primary tumour, suggesting that loss of ATRX/DAXX and ALT positivity are late events in the development of pNETs. 29 These studies identify previously unknown tumour suppressor genes in pNETs and show how mutated genes that are involved in chromatin remodelling can have a deep impact on epigenetic modification in pNETs, in particular highlighting epigenetic differences in the pNET subtypes. Identification of these epigenetic changes pave the way to new possible targeted therapies that could have an impact on patient prognosis.
MicroRNA. miRNAs represent one of the most abundant classes of gene-regulatory molecules that can influence the output of many protein-coding genes; however, few data have been reported on the role of miRNA in GEP-NET pathogenesis. 30 With regards to pNETs, Roldo et al. 31 assessed global miRNA expression in the normal pancreas (n = 12), pNETs (twelve insulinomas and twenty-eight non-functioning endocrine tumours) and four acinar carcinomas to evaluate the involvement of miRNA in malignant transformation and progression. Interestingly, expression of miR-103 and miR-107, when associated with a lack of expression of miR-155, was able to discriminate tumours from normal tissue, supporting the idea that miRNAs are involved in pancreatic tumorigenesis. Moreover, the authors report a set of ten miRNAs that are able to distinguish between endocrine and acinar tumours, and the possible association with either normal endocrine differentiation or endocrine tumorigenesis. Moreover, miR-21 overexpression in pNETs was strongly associated with both high Ki67 proliferation index and liver metastasis.
GASTROINTESTINAL NEUROENDOCRINE TUMOURS
GI-NETs comprise two-thirds of NETs. These tend to be nonfunctional and arise in three distinct locations: the foregut, midgut and hindgut. The incidence for small intestinal neuroendocrine tumour is estimated to be from 0.32/100 000 to 1.12/100 000/year; the incidence for rectal tumours is 0.86/100 000/year, and for gastric NETs 0.30/100 000/year. 1 Hindgut tumours tend to have a high proliferation index and poor overall survival. Similar to pNETs, treatment strategies are based on tumour stage, with early-stage tumours being amendable to surgery while systemic therapy remains the mainstay of treatment for patients with metastatic disease. All patients with small intestinal NETs should be considered potential candidates for curative surgery; in fact, curative resection of the primary tumour and locoregional lymph node metastases improves outcomes with an excellent 5-and 10-year survivals ranging from 80 to 100% according to disease stage.
1 Cytoreductive surgery should be considered when metastatic disease is localized or if 470% of tumour load is thought to be resectable, which may decrease endocrine and local symptoms and might help to improve systemic treatment. The use of somatostatin analogues is standard therapy in functioning NETs of any size, although its antitumour efficacy appears weak with respect to objective tumour response (5-10%); a disease stabilization of up to 50-60% has been reported. 32, 33 Molecular differences between GI-NETs and pNETs have been observed, suggesting that alternative mechanisms underlie the pathogenesis of these tumours (Table 1) .
Promoter methylation Considering RASSF1A, metastatic lesions from small bowel carcinoids show higher methylation of RASSF1A compared with primary tumours, whereas methylation of the cadherin-associated protein (CTNNB1) promoter is more frequent in metastatic lesions than in primary tumour and is not present in normal tissue.
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RASSF1A methylation seems to be restricted to foregut tumours, and there is no evidence of either RASSF1A or CTNNB1 methylation in appendiceal NETs, which are known to have a low probability to be metastatic. Zhang et al. 34 demonstrated that methylation of RASSF1A and CTNNB1 promoters were more frequent in metastatic lesions compared with the corresponding primary tumours (P = 0.013 and 0.004, respectively). 34 Moreover, methylation of RASSF1A and CTNNB1 was not observed in any of the appendiceal tumour examined (n = 6), suggesting that methylation of these genes may be involved in the development of foregut and midgut NETs rather than hindgut lesions. In vitro work presented by the same group further suggests that after treatment with the demethylating agent 5-aza-2′-deoxycytidine (5-aza-CdR or decitabine), RASSF1A mRNA was re-expressed, suggesting the clinical application of demethylating agents in this tumour type. 35 Recently, Fotouhi et al. 36 investigated promoter methylation of candidate genes and global methylation in forty-four small intestine NETs. Global hypomethylation was observed in tumours compared with normal ileal tissue. CTNNB1 expression correlated Figure 3 . The O6-alkylguanine DNA adduct, O6-meG, is removed by MGMT with a covalent transfer of the alkyl group to the active-site cysteine, leading to a restoration of guanine to normal. MGMT is inactivated and subjected to ubiquitin-mediated degradation, after a methyl group from O6-meG is received. When an O6-meG DNA adduct escapes MGMT repair, a base pair with thymine is formed during DNA replication; the mismatched base pair of the persistent O6-meGT is recognized by the mismatch repair pathway, resulting in double-stranded breaks and apoptosis.
Epigenetic and endocrine tumours P Mapelli et al with tumour size and stage, whereas low expression of RASSF1A and p16 was predictive of poor overall survival (P = 0.05 and P = 0.01, respectively). To investigate the possibility of reducing DNA methylation and restoring gene expression, NET cell lines were treated with 5-azacytidine. This resulted in restoration of expression of CTNNB1, p16 and RASSF1A supporting previous similar findings provided by Zhang et al.
When considering differential methylation patterns between pNETs and GI-NETs, and even between methylation status of differing sites of GI-NETs, controversial results have been reported.
Choi et al. 37 studied thirty-five GEP-NETs and observed that hypomethylation was more common in GI-NETs compared with pNETs and corresponding normal tissue. Using long interspersed nucleotide element 1 (LINE-1) and Alu methylation analyses, they found that hypomethylation of LINE-1 was higher (P = 0.05) in ileal carcinoid (n = 15) than in non-ileal tumours (n = 9), pNETs (n = 11) and tumours with lymph node metastasis (P = 0.02). Moreover, Alu methylation was inversely correlated with the methylation status of MGMT (P = 0.02). Conversely, Stricker et al. 38 identified a higher percentage of LINE1 hypomethylation in a cohort of fifteen pNETS and four GI-NETs; however, hypomethylation was present in 50% (n = 14) of gastric NETs and in 82% (n = 17) of small intestine NETs. A lower rate of hypomethylation was also observed in metastatic compared with nonmetastatic NETs. The different results reported by Choi et al. 37 and Stricker et al. 38 could be explained by the distribution analysis of these repetitive sequences in human genome: LINE-1 is more frequent in GC-poor regions, whereas Alu is more frequent in GC-rich regions, suggesting that there may be differences in the regulation of different repetitive sequences of human genome. [39] [40] [41] Arnold et al. 42 demonstrated additional differences between colorectal NETs (n = 34) and foremidgut NETs (n = 38). CIMP was more frequent in poorly differentiated colorectal NETs (59%) than in well-differentiated fore-/midgut NETs (29%). Furthermore, hindgut NETs had higher proliferation indexes (⩾20%) than welldifferentiated foremidgut ones (P o0.0001), in agreement with their poor differentiation. Interestingly, in these tumours CIMP correlated with higher Ki-67 indexes. 42 As briefly mentioned above, DNMTs 1, 3a and 3b are enzymes involved in DNA methylation; they affect promoter methylation status and have an important role in cancer development. 8, 9 Rahman et al. 43 examined sixty-three GEP-NETs and found that DNMTs 1, 3a and 3b were frequently expressed (87%, 81% and 75%, respectively) and that their expression was higher in stage IV tumours than in stage I/II tumours, with DNMT3a expression being higher in poorly differentiated NETs than in well-differentiated tumours (P o 0.01). Moreover, DNMT 3a and 3b were significantly less expressed in the midgut than in the foregut or hindgut NETs suggesting that overexpression of these enzymes could be related to tumorigenesis and progression of GEP-NETs. A positive correlation was also observed between DNMT1, 3a and 3b levels and MIB-1 proliferation index. Although the relationship between DNMT1 and the proliferation index, Ki-67, has been documented in several cancers, the association between overexpression of DNMT1, DNMT3a and DNMT3b with MIB-1 was first reported in this study, underlying the need for further investigations regarding the interaction of DNMT with other nuclear proteins involved in the cell cycle or proliferation.
La Rosa et al. 44 investigated possible diagnostic and prognostic markers in twenty-seven poorly differentiated NETs and twelve mixed adenoneuroendocrine carcinomas. Extensive methylation of GATA5, a transcription factor often inactivated by promoter hypermethylation in colorectal cancer, was present in 90% of tumours, whereas CIMP positivity was correlated with microsatellite instability in all cases, and was associated with better prognosis (P = 0.04). As also remarked by the authors, the important clinical implication of this latter result is that CIMPpositive tumours with MSI represents a distinct entity associated with a better prognosis than other cancers and, as aberrant gene methylation is a common abnormality in GI-NETs, specific epigenetic characterization of these tumours may provide avenues for the discovery of early diagnostic markers and for tumour-specific methylation profiles.
Furlan et al. 45 evaluated twenty-one colorectal neuroendocrine carcinomas showing methylation in 29% of samples with RASSF1, CASP8 and APC being the most frequently methylated genes. Moreover, patients with longest survival showed extensive gene hypermethylation and MSI, although this result was not statistically significant because of the small number of cases. Despite this, these findings emphasize the possibility of being able to identify a biologically distinct group of tumours. Recently, Kim et al. 46 evaluated the Wnt/β-catenin signalling in NETs and reported mutations of β-catenin and APC in NET cells. The expression of Wnt inhibitors including secreted Frizzledrelated proteins (SFRPs) were absent or markedly decreased in the human pancreatic carcinoid cell line (BON). Treatment with decitabine increased the expression of molecular inhibitors of Wnt, and further methylation analyses demonstrated that CpG islands of SFRP-1 were methylated also in NET tissues (12/20 GI-NET) suggesting that aberrant methylation of Wnt/β-catenin signalling can contribute to the pathogenesis of NETs, thus having important clinical implications for prognosis and treatment of these tumours.
Delgado et al. 47 investigated DNA methylation in twenty primary small intestine NETs and corresponding lymph node metastases. In agreement with previous results, 37 they found that CpG loci were less methylated in metastases compared with primary tumours, indicating global low methylation, and supporting the hypothesis that hypomethylation might also contribute to malignant behaviour through genomic instability. [47] [48] [49] In fact, whereas in most cases cancer progression and metastases appear to be associated with hypermethylation of gene promoters, this latter study illustrates that hypomethylation may also represent a possible epigenetic phenomenon contributing to malignant behaviour.
Histone modifications Few studies have assessed the role of histone modifications in GEP-NETs. Histone H1x is a member of the H1 histone family that stabilizes chromatin in a compact structure; it also acts as a structural protein, regulating gene expression, participating in chromatin-based processes such as DNA replication and repair, and therefore having a potential role in malignant transformation. 50 Warneboldt et al. 50 investigated the expression of H1x in thirteen primary NETs and a liver metastasis, and demonstrated an increased expression of H1x in NET tissues compared with normal tissues. Magerl et al. 51 studied demethylation of histone H3 at lysine 4 (H3K4diMe) in sixteen low-grade GI-NETs and reported a strong expression of H3Kdi4diME in 93% of samples, suggesting a potential role of histone H3K4 modification in intestinal NETs.
MicroRNA
On the basis of the hypothesis that miRNA could have a potential role in tumour development and progression, 52 Li et al.
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investigated the miRNA profile of twenty-four small intestinal NETs to assess whether miRNA could be considered as a potential biomarker for diagnosis and prognosis. In this study nine miRNAs were characterized: five of the nine were upregulated during tumour progression (miR-96, -182, -183, -196a and -200a) and four of the nine were downregulated (miR-31, -129-5p, -133a and -215), providing information that may lead to further insights into tumorigenesis and progression. 53 The specific role of miRNAs in GI-PET has not been completely validated yet, but these data confirm previous results from Ruebel et al. 54 who examined the differential expression of ninety-five miRNAs in eight matching primary and metastatic ileal carcinoids. In all samples, downregulation of miRNA-133a, -145, -146, -222 and -10b was observed in the primary tumour and corresponding metastases, whereas upregulation of miRNA-183, -488 and -19aþb was present in six of the eight metastases compared with primary tumours, suggesting differential pathogenesis in the development of tumour metastases in GI-NETs.
EPIGENETIC PROFILE OF NET AND DRUG TREATMENT
In many tumours, the presence of aberrant epigenetic modification pattern represents the rationale for the development of epigenetic cancer drugs, and tumour-specific epigenetic alterations or epigenetic mutations affect a variety of cancer-related genes. DNMT inhibitors and HDAC inhibitors have contributed to shape epigenetic cancer therapy.
The FDA-approved epigenetic drugs include the DNMT inhibitors 5-azacytidine (Vidaza) and decitabine (20-deoxy-5-azacytidine, Dacogen) and the HDAC inhibitors suberoy-lanilide hydroxamic acid (SAHA, Zolinza) and romidepsin (Istodax). 55 5-Azacytidine and decitabine are used for the treatment of myeloid leukaemias and they have shown significant clinical benefit in the treatment of myelodysplastic syndrome. 56, 57 Although these drugs are particularly effective at low doses, a direct link between DNA demethylation and clinical responses has not been demonstrated yet, and there are currently no established DNA methylation biomarkers that accurately predict patient responses. 58 Among HDAC inhibitors, SAHA and romidepsin are approved for the treatment of cutaneous T-cell lymphoma. 59, 60 Other HDAC inhibitors are currently undergoing clinical testing due to the excellent druggability of the HDAC enzyme family, which permits the development of potent isoenzyme-specific inhibitors. 61 Histone deacetylation synergistically interact with DNA methylation in the epigenetic silencing of cancer genes, and this finding provided the scientific rationale for various clinical trials where DNMT and HDAC inhibitors are used in combination. 62 Preclinical studies of targeted epigenetic therapies have provided promising outcome data in NETs as well, based on the reversibility of epigenetic changes that can occur in GEP NETs such as DNA methylation and chromatin modifications (Figure 4) . DNMT inhibitors DNMT inhibitors (DNMTIs) have shown clinical efficacy in the management of haematological malignancies, but have not been extensively investigated in NETs. 50 Habbe et al. 63 carried out one of the first studies evaluating the potential therapeutic role of the demethylating agent, decitabine, in vitro. They reported differential expression of forty-eight genes following decitabine treatment including high expression of 25/48 (52%) genes. Interestingly, decitabine led to re-expression of cofillin, whereas matriptase expression levels were significantly lower. This finding is of particular interest as these genes are involved in cellular proliferation, apoptosis and development of metastases.
Further effects of 5-aza-2′-deoxycytidine have been reported using three carcinoid cell lines-human midgut (CDNT2.5), pulmonary (H727) and gastrointestinal (BON). A dose-dependent reduction in cell proliferation and growth was observed in all three cell lines with a reduction in neuroendocrine markers observed in the midgut line. According to these preliminary results, patients with NETs could potentially be treated with DNMTIs in order to control tumour growth and inhibit release of bioactive peptides. 64 The antiproliferative effect of decitabine has been tested in different tumour histotypes with encouraging results. [65] [66] [67] [68] [69] [70] [71] However, its anticancer activity in patients with refractory and metastatic solid tumours led to only limited responses because of difficulty to calibrate steady-state blood concentration and a narrow therapeutic index, resulting in dose-limiting haematologic toxicities. [72] [73] [74] Therefore, considering that the therapeutic potential of decitabine is hampered by its systemic instability, further studies are required to improve drug stability in solution and efficacy of delivery, in order to minimise toxicities, and to prolong epigenetic outcomes. 75 Histone deacetylation inhibitors HDACi have been tested in GEP-NETs with promising results, although the toxicity profile observed is similar to that observed with DNMTI. 76 Baradari et al. 77 investigated the antineoplastic effects of three different HDACi, trichostatin A, sodium butyrate and MS-275, on growth and apoptosis of GEP-NET cell lines, CM and BON. These HDACi caused a dose-dependent inhibition of proliferation in both cell lines, inducing apoptosis. In this study the possible role of combined treatment using MS-275 together with somatostatin or octreotide was investigated; however, neither somatostatin nor octreotide augmented the antiproliferative effect of MS-275 in the cell lines examined.
Valproic acid (VPA), a class I and IIa HDACi, is able to suppress NET cell growth through upregulation of Notch1, a transmembrane receptor that regulates gene transcription and acts as tumour-suppressor gene. 78, 79 These findings were later corroborated in studies where NET cells were treated with VPA or suberoyl bis-hydroxamic acid and lithium chloride. A decrease in tumour markers and upregulation of Notch1 were confirmed with combination therapy, suggesting that low-dose combinations of these drugs may provide a viable therapeutic approach for NETs. 80 VPA was tested in a clinical study including eight patients with low-grade NET, treated with 500 mg of oral VPA twice a day and followed up for 12 months or until disease progression. Before treatment, Notch1 signalling was absent in all tumours, whereas its upregulation was observed after treatment. One patient had a partial response with a 40-fold increase in Notch1 mRNA levels, whereas four patients had stable disease as best tumour response. Tumour markers improved in five patients. Overall, treatment with VPA was well tolerated. 81 Although the number of patients was small, this study demonstrates that activation of the Notch1 pathway could lead to clinical responses in this patient population.
A phase II study including fifteen patients with NETs aimed at assessing the objective response and toxicity of depsipeptide, another HDACi targeting HDACI and II, that was prematurely terminated because of an unexpected high number of serious cardiac adverse events. 82 Cardiotoxicity has been observed with other HDAC inhibitors, such as tricostatin, and may limit further development of these agents clinically.
Recently, Strosber et al. 83 retrospectively evaluated the efficacy of capecitabine and temozolomide in thirty patients with metastatic pNETs. Twenty-one (70%) patients achieved an objective radiographic response with the median progressionfree survival of 18 months and overall survival rate at 2 years of 92%. Although the synergistic relationship between capecitabine and temozolomide is not fully understood, the authors hypothesized that the DNA damage induced by capecitabine can reduce the repair activity of MGMT, thereby potentiating the effects of temozolomide on DNA replication. As demonstrated in this study, the combination of these two drugs is associated with an exceptionally promising objective response, a good overall survival and, interestingly, toxicity rates that are considerably lower than those observed with streptozocin-based regimens. 83 This regimen is currently undergoing clinical trial.
CONCLUSIONS
Neuroendocrine tumours have different cellular origins and epigenetic patterns that can potentially have an impact on the tumorigenic process. We presented an overview on the current knowledge of epigenetic modifications in GEP-NETs. As these are rare, heterogeneous neoplasms, the majority of the reported studies include small number of samples and patients. Despite this limitation, we present significant findings that may have implications for a novel therapeutic approach in this disease type. Although the routine use of demethylating agents has been limited by dose-limiting toxicity, this may change in the future with the introduction of new, class-specific agents, thereby improving outcomes in this disease area.
